Published on 3 Nov 2023 on Zacks via Yahoo Finance
Corcept (CORT) Beats on Q3 Earnings, Raises '23 Sales View
Corcept Therapeutics Incorporated CORT reported third-quarter 2023 earnings of 28 cents per share, which beat the Zacks Consensus Estimate of 22 cents. The company had reported earnings of 30 cents in the year-ago quarter.
Revenues increased 22% year over year to $123.6 million. The figure beat the Zacks Consensus Estimate of $118 million. The top line solely comprises product sales of Cushing’s syndrome drug, Korlym.
Quarter in Detail